KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $1.7 million.

  • Adaptive Biotechnologies' Cash from Financing Activities rose 411000.0% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 431393.03%. This contributed to the annual value of $241000.0 for FY2024, which is 8926.5% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Cash from Financing Activities of $1.7 million as of Q3 2025, which was up 411000.0% from $1.6 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Cash from Financing Activities' 5-year high stood at $125.5 million during Q3 2022, with a 5-year trough of $6000.0 in Q4 2022.
  • For the 5-year period, Adaptive Biotechnologies' Cash from Financing Activities averaged around $9.0 million, with its median value being $1.6 million (2025).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Cash from Financing Activities crashed by 9998.65% in 2023, and later soared by 1228863.64% in 2025.
  • Adaptive Biotechnologies' Cash from Financing Activities (Quarter) stood at $3.3 million in 2021, then plummeted by 99.82% to $6000.0 in 2022, then surged by 1350.0% to $87000.0 in 2023, then skyrocketed by 45.98% to $127000.0 in 2024, then skyrocketed by 1225.98% to $1.7 million in 2025.
  • Its Cash from Financing Activities was $1.7 million in Q3 2025, compared to $1.6 million in Q2 2025 and $5.5 million in Q1 2025.